KRAS and cancer: Among more than 250 verified SHs genes within all KRAS mutated TCGA cancers, we found the highest co-occurrence (≥30%) of genomic alterations with KRAS for four palmitoyl and palmitoleoyl hydrolases (i.e., LYPLA2, NOTUM, PPT2, and ACOT7, BH adjusted Fisher’s P < 0.01, Fig. 7c), including the here dysregulated LYPLA2, the major indicator of LUAD aggressiveness.